USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market
A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market
RELEASE DATE
28-Apr-2014
28-Apr-2014
REGION
North America
North America
Research Code: NDDC-01-00-00-00
SKU: LS00122-NA-MR_16963
$3,950.00
Special Price $2,962.50 save 25 %
In stock
SKU
LS00122-NA-MR_16963
Description
The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the introduction of novel therapies that fill therapeutic gaps left by available products. Comprehensive information on market background and global overview and analysis of drug development, detailed product and pipeline analysis by market segment, drug class, and stage of development, and detailed product profiles for key marketed and late-stage products is included in the study. Also included are time-sensitive details such as new product launch timelines, cardiovascular outcomes trials timelines, and patent expirations.
Table of Contents
Executive Summary
Executive Summary (continued)
Recent Market Developments
Recent Market Developments (continued)
New Market Opportunities
Companies to Watch
Methodology and Scope
Introduction
Disease Classification and Diagnostics—Type 2 Diabetes
Disease Classification and Diagnostics—Type 1 Diabetes
Diagnostic Criteria
Market Segmentation
Market Segmentation (continued)
Market Segmentation (continued)
Market Segmentation (continued)
Market Segmentation (continued)
Timeline of New Product Launches
Competitive Landscape—Insulin Segment, Count of Marketed and Pipeline Products
Competitive Landscape—Insulin Segment, Marketed and Pipeline Products
Marketed Product Analysis—Insulin Segment
Marketed Product Analysis—Insulin Segment (continued)
Pipeline Analysis—Insulin Segment, Products in Late-stage Clinical Development
Pipeline Analysis—Insulin Segment, Products in Late-stage Clinical Development (continued)
Pipeline Analysis—Insulin Segment, Products in Mid-stage Clinical Development
Pipeline Analysis—Insulin Segment, Products in Early-stage Clinical Development
Pipeline Analysis—Insulin Segment, Products in Early-stage Clinical Development (continued)
Competitive Landscape—Non-insulin Segment, Count of Marketed and Pipeline Products
Competitive Landscape—Non-insulin Segment, Late-stage and Marketed Products
Competitive Landscape—Non-insulin Segment, Early- and Mid-stage Pipeline Products
Marketed Product Analysis—Non-insulin Segment
Marketed Product Analysis—Non-insulin Segment (continued)
Marketed Product Analysis—Non-insulin Segment (continued)
Marketed Product Analysis—Non-insulin Segment (continued)
Marketed Product Analysis—Non-insulin Segment (continued)
Pipeline Analysis—Non-insulin Segment, Products in Late-stage Clinical Development
Pipeline Analysis—Non-insulin Segment Products in Late-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment Products in Late-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development
Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Mid-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development
Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)
Pipeline Analysis—Non-insulin Segment, Products in Early-stage Clinical Development (continued)
Patent Expirations
Patent Expirations (continued)
Cardiovascular Outcomes Trials Timeline
Comparative Product Profiles of Promising Late-stage Candidates
Comparative Efficacy Analysis
Comparative Efficacy Analysis (continued)
Comparative Efficacy Analysis Discussion
Marketed Product Profiles—Rapid-acting Insulin
Marketed Product Profiles—Intermediate-acting/Pre-mix Insulin
Marketed Product Profiles—Basal Insulin
Marketed Product Profiles—DPP-4 Inhibitors
Marketed Product Profiles—DPP-4 Inhibitors (continued)
Marketed Product Profiles—GLP-1 Agonists/Analogs
Marketed Product Profiles—GLP-1 Agonists/Analogs (continued)
Marketed Product Profiles—SGLT2 Inhibitors
Conclusions and Recommendations
The Last Word—3 Big Predictions
The Last Word—Discussion
The Last Word—Discussion (continued)
The Last Word—Discussion (continued)
Legal Disclaimer
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Popular Topics
The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the introduction of novel therapies that fill therapeutic gaps left by available products. Comprehensive information on market background and global overview and analysis of drug development, detailed product and pipeline analysis by market segment, drug class, and stage of development, and detailed product profiles for key marketed and late-stage products is included in the study. Also included are time-sensitive details such as new product launch timelines, cardiovascular outcomes trials timelines, and patent expirations.
| No Index | No |
|---|---|
| Podcast | No |
| WIP Number | NDDC-01-00-00-00 |
| Is Prebook | No |